Dyne Therapeutics Inc (NASDAQ: DYN) is -78.61% lower on its value in year-to-date trading and has touched a low of $6.36 and a high of $47.45 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DYN stock was last observed hovering at around $9.38 in the last trading session, with the day’s loss setting it -0.14%.
Currently trading at $9.24, the stock is 2.47% and -16.37% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.31 million and changing -1.49% at the moment leaves the stock -46.92% off its SMA200. DYN registered -60.78% loss for a year compared to 6-month loss of -34.51%. The firm has a 50-day simple moving average (SMA 50) of $11.0482 and a 200-day simple moving average (SMA200) of $17.406376.
The stock witnessed a -13.08% gain in the last 1 month and extending the period to 3 months gives it a -14.29%, and is -1.70% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.57% over the week and 6.34% over the month.
Dyne Therapeutics Inc (DYN) has around 191 employees, a market worth around $1.31B and $0.00M in sales. Distance from 52-week low is 45.28% and -80.53% from its 52-week high. The company has generated returns on investments over the last 12 months (-53.42%).
The EPS is expected to shrink by -15.32% this year
283.0 institutions hold shares in Dyne Therapeutics Inc (DYN), with institutional investors hold 91.31% of the company’s shares. The shares outstanding are 113.63M, and float is at 106.08M with Short Float at 15.43%. Institutions hold 90.84% of the Float.
The top institutional shareholder in the company is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC with over 8.02 million shares valued at $283.03 million. The investor’s holdings represent 8.6697 of the DYN Shares outstanding. As of 2024-06-30, the second largest holder is FCPM III SERVICES B.V. with 7.85 million shares valued at $276.86 million to account for 8.4808 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 7.39 million shares representing 7.9853 and valued at over $260.69 million, while RTW INVESTMENTS, LP holds 6.9044 of the shares totaling 6.39 million with a market value of $225.4 million.
Dyne Therapeutics Inc (DYN) Insider Activity
The most recent transaction is an insider purchase by Cox John, the company’s CEO & President. SEC filings show that Cox John bought 100,000 shares of the company’s common stock on Jul 14 ’25 at a price of $9.11 per share for a total of $0.91 million. Following the purchase, the insider now owns 0.24 million shares.
